Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorHenderson, Andrew-
dc.contributor.authorCheng, Matthew P-
dc.contributor.authorChew, Ka Lip-
dc.contributor.authorCoombs, Geoffrey W-
dc.contributor.authorDavis, Joshua S-
dc.contributor.authorGrant, Jennifer M-
dc.contributor.authorGregson, Dan-
dc.contributor.authorGiulieri, Stefano G-
dc.contributor.authorHowden, Benjamin P-
dc.contributor.authorLee, Todd C-
dc.contributor.authorNguyen, Vi-
dc.contributor.authorMora, Jocelyn M-
dc.contributor.authorMorpeth, Susan C-
dc.contributor.authorRobinson, James O-
dc.contributor.authorTong, Steven Y C-
dc.contributor.authorVan Hal, Sebastiaan J-
dc.identifier.citationThe Journal of Antimicrobial Chemotherapy 2023-06-01; 78(6)en_US
dc.description.abstractThere is clinical uncertainty over the optimal treatment for penicillin-susceptible Staphylococcus aureus (PSSA) infections. Furthermore, there is concern that phenotypic penicillin susceptibility testing methods are not reliably able to detect some blaZ-positive S. aureus. Nine S. aureus isolates, including six genetically diverse strains harbouring blaZ, were sent in triplicate to 34 participating laboratories from Australia (n = 14), New Zealand (n = 6), Canada (n = 12), Singapore (n = 1) and Israel (n = 1). We used blaZ PCR as the gold standard to assess susceptibility testing performance of CLSI (P10 disc) and EUCAST (P1 disc) methods. Very major errors (VMEs), major error (MEs) and categorical agreement were calculated. Twenty-two laboratories reported 593 results according to CLSI methodology (P10 disc). Nineteen laboratories reported 513 results according to the EUCAST (P1 disc) method. For CLSI laboratories, the categorical agreement and calculated VME and ME rates were 85% (508/593), 21% (84/396) and 1.5% (3/198), respectively. For EUCAST laboratories, the categorical agreement and calculated VME and ME rates were 93% (475/513), 11% (84/396) and 1% (3/198), respectively. Seven laboratories reported results for both methods, with VME rates of 24% for CLSI and 12% for EUCAST. The EUCAST method with a P1 disc resulted in a lower VME rate compared with the CLSI methods with a P10 disc. These results should be considered in the context that among collections of PSSA isolates, as determined by automated MIC testing, less than 10% harbour blaZ. Furthermore, the clinical relevance of phenotypically susceptible, but blaZ-positive S. aureus, remains unclear.en_US
dc.titleA multi-site, international laboratory study to assess the performance of penicillin susceptibility testing of Staphylococcus aureus.en_US
dc.typeJournal Articleen_US
dc.identifier.journaltitleThe Journal of Antimicrobial Chemotherapyen_US
dc.identifier.affiliationInfection Management Services, Princess Alexandra Hospital, Brisbane, Australia.en_US
dc.identifier.affiliationDepartment of Medicine, and Laboratory Medicine, McGill University Health Centre, Montreal, Canada.en_US
dc.identifier.affiliationDepartment of Laboratory Medicine, National University Hospital, Singapore, Singapore.en_US
dc.identifier.affiliationDepartment of Antimicrobial Resistance, and Infectious Diseases Research Laboratory, Murdoch University, Murdoch, Australia.en_US
dc.identifier.affiliationHunter Medical Research Institute, University of Newcastle, Newcastle, Australia.;Department of Infectious Diseases, John Hunter Hospital, Newcastle, Australia.en_US
dc.identifier.affiliationDepartment of Medicine, Vancouver Coastal Health, Vancouver, Canada.;Department of Medicine, University of British Columbia, Vancouver, Canada.en_US
dc.identifier.affiliationDepartment of Pathology, Laboratory Medicine, and Medicine, Cummings School of Medicine at The University of Calgary, Calgary, Canada.en_US
dc.identifier.affiliationDepartment of Microbiology, and Immunology, The University of Melbourne, Melbourne, Australia.;Victorian Infectious Diseases Services, The Royal Melbourne Hospital, Melbourne, Australia.en_US
dc.identifier.affiliationMicrobiological Diagnostic Unit Public Health Laboratory, The Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.;Department of Infectious Diseases, Austin Hospital, Heidelberg, Australia.en_US
dc.identifier.affiliationDepartment of Medicine, McGill University, Montreal, Canada.en_US
dc.identifier.affiliationInfectious Diseasesen_US
dc.identifier.affiliationThe Peter Doherty Instituteen_US
dc.identifier.affiliationMicrobiology Laboratory, Middlemore Hospital (Counties Manukau Te Whatu Ora), Otahuhu, New Zealand.;Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand.en_US
dc.identifier.affiliationDepartment of Infectious Diseases, Royal Perth Hospital, Perth, Australia.;Department of Infectious Diseases, Fiona Stanley Hospital, Murdoch, Australia.en_US
dc.identifier.affiliationDepartment of Microbiology, and Infectious Diseases, Royal Prince Alfred Hospital, Missenden Road, Camperdown, NSW 2050, Sydney, Australia.;School of Medicine, The University of Sydney, Sydney, Australia.en_US
dc.identifier.pubmedid37071589-, Stefano G
item.fulltextNo Fulltext-
item.openairetypeJournal Article-
item.languageiso639-1en- Diseases- Diseases-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

checked on Jun 14, 2024

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.